I've worked the overnight shift at a specialty exotic veterinary clinic outside Tucson, Arizona, for six years now, and I thought I'd seen every kind of owner walk through that door — snake people, tarantula people, the guy who brought in a three-foot iguana named Gerald wrapped in a Cardinals blanket. But nothing prepared me for Marisol.
She showed up on a Tuesday close to closing, carrying a plastic storage bin with holes drilled in the lid, and inside was an axolotl the size of my forearm, pale pink with feathery gills like something out of a kid's drawing. She said his name was Boone. She wasn't there because he was sick. She was there because she'd read something online about axolotl slime and cancer, and she wanted to know if it was true, and if it was, whether there was anything she could do with what Boone produced naturally when he was stressed or handled.
I remember thinking, lady, it's eleven at night, I have three dogs in recovery and a cat that just ate a shoelace. But something about the way she held that bin — both arms under it, like it might slip — made me stop and actually listen.
Turned out her sister Denise had been diagnosed with triple-negative breast cancer fourteen months earlier. Denise had gone through the standard rounds — surgery, then chemo that wrecked her from the inside out, and the oncologist in Phoenix had just told her the latest scan showed activity again. Marisol wasn't a scientist. She managed a UPS Store. But she'd fallen into some research rabbit hole at two in the morning, the way people do when someone they love is running out of options, and she'd landed on a study — PLOS ONE, published earlier that year — about peptides in axolotl mucus that killed MRSA and, more strikingly, triggered cell death in breast cancer cells while leaving healthy tissue alone.
I told her what I knew, which wasn't much beyond what she'd already found. That the research was real — a team out of Germany, working with captive-bred axolotls, had identified twenty-two peptide candidates from the slime, and three of them went after cancer cells with a precision nobody expected, like the peptides could tell the difference between a healthy cell and a malignant one and only punched holes in the one that deserved it. I told her it was early. Petri dish and lab-animal early. Years from anything you could put in a syringe, let alone anything Boone's own slime could replicate at home in a plastic bin.
She nodded at that, but she didn't put the bin down.
What got me wasn't the science — I'm not qualified to have opinions on peptide synthesis. What got me was watching her handle Boone on our exam table, running her fingers along his flank so he'd release a little of that slime coating, catching it on a clean glass slide like she'd practiced this at home a hundred times, which, it turned out, she had. She'd been keeping a log. Dates, amounts, how much he produced when he was calm versus stressed. She had this idea — half-formed, she admitted it herself — that if she couldn't get Denise into some trial in Boston or Houston that was still probably two years from recruiting patients, maybe she could at least understand the animal better. Be ready. Learn everything there was to learn about him in case, someday, that knowledge mattered.
I didn't have the heart to tell her that home slime collection wasn't going anywhere near her sister's bloodstream, not without a decade of clinical trials standing between here and there. Our clinic vet, Dr. Feldstein, came in around midnight because I called her — I wasn't equipped to talk someone through this alone — and she was gentler about it than I would've been. She sat with Marisol for almost forty minutes. Explained the difference between a peptide identified in a lab and something safe to introduce into a human body. Explained that the reason this research mattered wasn't that Denise could use it next month, but that it might mean something for someone's kid, ten or fifteen years down the line, if the funding held and the trials went well and nobody let the species go extinct in the meantime — axolotls are basically gone from the wild now, down to a sliver of canal habitat near Mexico City.
Marisol cried a little at that part. Not the sad kind, or not only the sad kind — more like something had been confirmed that she already suspected but needed a person in scrubs to say out loud.
Here's the thing I keep coming back to, the part I didn't expect from a Tuesday night shift. Two weeks later Marisol came back, not with Boone this time, just herself, and she'd printed out the actual paper — all fourteen pages, some sections highlighted in yellow — and handed it to Dr. Feldstein along with a check for four hundred dollars made out to a listed axolotl conservation fund at a university lab in Ohio that does the kind of habitat and breeding work that keeps species like Boone's from disappearing before science catches up to what they're capable of. She said she couldn't fix Denise's scan results with that check. But she could make sure that whatever happens with the next round of trials, there'd still be axolotls left for somebody to study.
She also brought a second, smaller container. New arrival — a juvenile she'd named Poppy, from a breeder in Tempe. Said one axolotl for hope and one for backup felt right, given everything.
Denise's next scan is scheduled for October. I don't know how that one turns out. What I do know is that somewhere in a lab that neither Marisol nor I will ever see, a peptide extracted from an animal not much bigger than a housecat's paw is being tested against cells that look almost exactly like the ones inside her sister — and that on a Tuesday night in the Sonoran Desert, a UPS Store manager decided that wasn't a coincidence worth ignoring.
